[Radioimmunotherapy with (90)Y-Ibritumomab tiuxetan].
Brockmann
H
H
Klinik und Poliklinik für Nuklearmedizin des Universitätsklinikums Bonn. Holger.Brockmann@ukb.uni-bonn.de
Biersack
H-J
HJ
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D000075202:Contraindications; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy*; D016499:Radioimmunotherapy / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan